Skip to content
TrialScanner

NCT02743351

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Phase 1/Phase 2CompletedFATELead

Registry record

Lead sponsor
Fate Therapeutics
Conditions
Hematologic Malignancies; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia
Primary completion
Dec 4, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02743351 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02743351: Study of ProTmune for... | TrialScanner